Canadian Journal of Anaesthesia

, Volume 36, Issue 1, pp 64–74 | Cite as

monoamine oxidase inhibitors revisited

  • Douglas G. Wells
  • Andrew R. Bjorksten
Review article


Until recently, traditional teaching has been to discontinue MAOI therapy two to three weeks before surgery. The literature and texts relating to the concurrent use of MAOI’s with anaesthesia are confusing, outdated and often contradictory. Significant adverse drug reactions can and have occurred in a minority of patients receiving MAOI’s. The true incidence of such reactions is unknown. While there are several recent clinical reports indicating the safety of these agents in combination with anaesthesia, only small numbers of patients are described in each series. Until it is possible to define those individual patients in whom adverse reactions are likely to occur, all patients must be assumed to be at some level of potential risk.

However, assuming administration in appropriate doses and for appropriate indications, patients can and likely should continue to receive MAOI therapy. A final decision on the administration of anaesthesia in the presence of MAOI therapy can only be made by an anaesthetist familiar with the pharmacology of the MAO system and its inhibitors.

Key words

interactions (drug): monoamine oxidase inhibitors sympathomimetic amines meperidine barbiturates pharmacology: monamine oxidase inhibitors 


  1. 1.
    Zisoo kS. Side effects of isocarboxazid. J Clin. Psych 1984; 45: 53–8.Google Scholar
  2. 2.
    Anthony M, Lance JW. Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 1969; 21: 263–8.PubMedGoogle Scholar
  3. 3.
    Selikoff IJ, Robitzek EH. Tuberculosis chemotherapy with hydrazine derivatives of isonicotinic acid. Dis Chest 1952; 21: 3.Google Scholar
  4. 4.
    Zeller EA, Barsky J, Fouts JR, Kircheimer WF, Van Orden LS. Influence of isonicotinic and hydrazine (INH) and l-isonicotinyl-2-isopropyl hydrazide (IIH) on bacterial and mammalian enzymes. Experentia (Basel) 1952; 8: 349–50.CrossRefGoogle Scholar
  5. 5.
    Kline NS. Clinical experience with iproniazid (marsilid). J Clin Exp Psychopathol 1958; 19: 72–8.PubMedGoogle Scholar
  6. 6.
    Goldberg LI. Monoamine oxidase inhibitors: adverse reactions and possible mechanisms. JAMA 1964; 190: 132–8.Google Scholar
  7. 7.
    Sheehan DV, Claycomb JB. The use of MAO inhibitors in clinical practice.In: Psychiatric Medicine Update, Manschreck TC, Murray GB (Eds). Massachusetts General Hospital reviews for physicians, New York, Elsevier 1984; 143–62.Google Scholar
  8. 8.
    Biel H. Monoamine oxidase inhibitor antidepressants. Structure activity relationships.In: Principles of Psychopharmacology, Clark WG, Del Guidice J (Eds). New York: Academic Press 1970; 269–78.Google Scholar
  9. 9.
    Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between MAO inhibitors and foodstuffs. Br J Psychiatry 1967; 113: 349–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Singer TP, Van Korff RW, Murphy DL. Monoamine oxidase: structure, function and altered functions. New York: Academic Press 1979; 477–96.Google Scholar
  11. 11.
    Murphy DL, Garrick NA, Aulakh CS, Cohen RM. New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. J Clin Psych 1984; 45: 37–43.Google Scholar
  12. 12.
    Johnston JP. Some observations upon a new monoamine oxidase in brain tissue. Biochem Pharmacol 17: 1285–97.Google Scholar
  13. 13.
    Cantham RM, Pintar JE, Haseltine FP et al. Differences in the structure of A and B forms of human monoamine oxidase. J Neurochem 1981; 37: 363–72.CrossRefGoogle Scholar
  14. 14.
    Brown GK, Powell JF, Craig TW. Molecular weight differences between human platelet and placental monoamine oxidase. Biochem Pharmacol. 1980; 29: 2595–603.PubMedCrossRefGoogle Scholar
  15. 15.
    Denny RM, Fritz RR Patel NT et al. Human liver MAO-A and MAO-B separated by immunoaffinity chromatography with MAO-B-specific monoclonal antibody. Science 1982 215: 1400–3.CrossRefGoogle Scholar
  16. 16.
    Tipton KF,Fowler CJ,Houslay MD, Specificities of the two forms of monoamine oxidase.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982; 87-99.Google Scholar
  17. 17.
    Suzuki O,Katsumata Y,Oya H. Substrate specificity of type A and type B monoamine oxidase.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Usdin E, Nagatsu T (Eds). 1982; 74–86.Google Scholar
  18. 18.
    Fowler CJ, Ross SB. Selective inhibitors of monoamine oxidase A and B; biochemical, pharmacological and clinical properties. Med Res Reviews 1984; 4: 323–58.CrossRefGoogle Scholar
  19. 19.
    Lewinsohn R, Glover V, Sandler M, Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol 1980; 29: 1221–30.PubMedCrossRefGoogle Scholar
  20. 20.
    Glover V, Sandler M. Clinical chemistry of monoamine oxidase. Cell Biochem. Funct 1986; 4: 89–97.PubMedCrossRefGoogle Scholar
  21. 21.
    Schnaitman C, Erwin VG, Greenawalt JW. The submitochondrial localisation of monoamine oxidase. J Cell Biol 1967; 32: 719–35.PubMedCrossRefGoogle Scholar
  22. 22.
    Blaschko H. The natural history of amine oxidases. Physiol Biochem Pharmacol 1974; 70: 83–148.CrossRefGoogle Scholar
  23. 23.
    Glover V, Sandler M. Clinical chemistry of monoamine oxidase. Cell Biochem. Funct 1986; 4: 89–97.PubMedCrossRefGoogle Scholar
  24. 24.
    Schildkrant JI. The catecholamine hypothesis of affective disorders. A review of the supporting evidence. Am J Psychiatry 1963; 122: 509–22.Google Scholar
  25. 25.
    Neff NH, Costa E. The influence of monoamine oxidase inhibition on catecholamine synthesis. Life Sciences 1966; 5: 951–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Lin RC, Neff NH, Nga SH et al. Turnover rates of serotonin and norepinephrine in brain of normal and pargyline-treated rats. Life Sciences 1969; 8: 1077–84.PubMedCrossRefGoogle Scholar
  27. 27.
    Kapin IJ. False transmitters revisited: their role in the hypotensive action of MAO inhibitors.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982.Google Scholar
  28. 28.
    Finberg JPM. Effects of selective inhibition of MAO types A and B on peripheral sympathetic function.In: Monoamine Oxidase: Basic and Clinical Frontiers. Kamijo E, Uskin E, Nagatsu T (Eds). 1982.Google Scholar
  29. 29.
    Aghajanian GK. Influence of drugs on the firing of serotonin-containing neurons in brain. Fed Proc Am Soc Exp Biol 1972; 31: 91–6.Google Scholar
  30. 30.
    Campbell IC, Murphy DL, Gallager DW et al. Neurotransmitter related adaption in the central nervous system following chronic monoamine oxidase inhibition.In: Monoamine oxidase: structure, function and altered functions. Singer TP, Von Korff RW, Murphy DL (Eds). New York, Academic Press 1979.Google Scholar
  31. 31.
    Cohen RM, Anlakh CS, Campbell K et al. Functional subsensitivity of a-adrenoreceptors accompanies reductions in yohimbine binding after clorgyline treatment. Eur J Pharmacol 1982; 81: 145–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Simpson GM, White K. Tyrarnine studies and the safety of MAOI drugs. J Clin Psychiatry 1984; 45: 59–61.PubMedGoogle Scholar
  33. 33.
    Mann JJ, Aarons SF, Frances AJ, Brown RD. Studies of selective and reversible monoamine oxidase inhibitors. J Clin Psychiatry 1984; 45: 62–6.PubMedGoogle Scholar
  34. 34.
    Lader MH, Sakalis G, Tansella M. Interaction between sympathetic amines and a new monoamine oxidase inhibitor. Psychopharmacologia 1972; 18: 118–23.CrossRefGoogle Scholar
  35. 35.
    Pare CMB. The present status of monoamine oxidase inhibitors. Brit J Psychiatry 1985; 146: 576–84.CrossRefGoogle Scholar
  36. 36.
    Birkmayer W, Riederer P, Yondim MBH. (-)deprenyl in the treatment of Parkinson’s disease. Clin Neuropharmac 1982; 5: 195–230.CrossRefGoogle Scholar
  37. 37.
    Elsworth JD, Glover V, Reynolds GP et al. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the “cheese effect.” Psychoparmacology 1978; 57: 33–8.CrossRefGoogle Scholar
  38. 38.
    Knoll J. The possible mechanisms of action of (-)deprenyl in Parkinson’s disease. J Neural Transmission 1978; 43: 177–98.CrossRefGoogle Scholar
  39. 39.
    Richards LE, Burger A. Mechanism-based inhibitors of monoamine oxidase. Prog Drug Res 1987; 30: 205–19.Google Scholar
  40. 40.
    Benedetti MS, Boucher T, Carlsson A, Fowler CJ. Intestinal metabolism of tyrarnine by both forms of monoamine oxidase in the rat. Biochem Pharmacol 1983; 32: 47–52.PubMedCrossRefGoogle Scholar
  41. 41.
    Hedley ED, Snyder SH. Relationship between the action of monoamine oxidase inhibition on the noradrenaline uptake system and their antidepressant efficacy. Nature 1968; 220: 1330–1.CrossRefGoogle Scholar
  42. 42.
    LaRoche MJ, Brodie BB. Lack of relationship between inhibition of monoamine oxidase and potentiation of hexobarbital hypnosis. J Pharmacol Exp Ther 1960; 130: 134–7.PubMedGoogle Scholar
  43. 43.
    Bowman WC, Rand MJ. A Textbook of Pharmacology (2nd ed). Blackwell Scientific Publications, Oxford 1980; 11. 7–11.11.Google Scholar
  44. 44.
    Mantle TJ, Tipton KF, Garrett NJ Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol 1976; 25: 2073–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Fowler CJ, Callingham BA, Mantle TJ, Tipton KF. The effect of lipophilic compounds upon the activity of rat liver mitochondrial monoamine oxidase -A and -B. Biochemical Pharmacol 1980; 29: 1177–83.CrossRefGoogle Scholar
  46. 46.
    Yasuhara, H, Wada I, Sakamoto K. Inhibitory effects of B-blockers and local anaesthetics on monoamine oxidase and their membrane effects.In: Monoamine oxidase: basic and clinical frontiers. Kamija K, Usdin E, Nagatsu T (Eds). Excerpta Medica, Amsterdam 1982; 251–61.Google Scholar
  47. 47.
    Roth JA. Inhibition of human brain type B monoamine oxidase by tricyclic psychoactive drugs. Mol Pharmacol 1978; 14: 164–71.PubMedGoogle Scholar
  48. 48.
    Roizen MF. Anesthetic implications of concurrent disease.In: Miller RD (Ed). Anesthesia. 2nd ed. New York: Churchill Livingstone, 1986; 331–2.Google Scholar
  49. 49.
    Perks ER. Monoamine oxidase inhibitors. Anaesthesia 1964; 19: 376–86.PubMedCrossRefGoogle Scholar
  50. 50.
    Davidson J, Zung WW, Walker JI. Practical aspects of MAI inhibitor therapy. J Clin Psychiatry 1984; 45 (sec. 2): 81–4.PubMedGoogle Scholar
  51. 51.
    Jenkins LC, Graves HB. Potential hazards of psychoactive drugs in association with anaesthesia. Can Anaesth Soc J 1965; 12: 121–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Brown TCK, Cass NM. Beware - the use of MAO inhibitors is increasing again. Anaesth Intensive Care 1979; 7: 65–8.PubMedGoogle Scholar
  53. 53.
    Sheean DV, Claycomb JB, Kouretas N. Monoamine oxidase inhibitors: prescription and patient management. Int J Psych Med 1980-1981; 10(2): 99–121.Google Scholar
  54. 54.
    Evans-Prosser CDG. The use of pethidine and morphine in the presence of monoamine oxidase inhibitors. Br J Anaesth 1968; 40: 279–82.PubMedCrossRefGoogle Scholar
  55. 55.
    Wong KC, Puerto AX, Puerto BA, Blatnick RA. Influence of imipramine and pargyline on the arrythmogenicity of epinephrine during halothane, enflurane or methoxyflurane anaesthesia in dogs. Life Sciences 1980; 27: 2675–8.PubMedCrossRefGoogle Scholar
  56. 56.
    Braverman B, Ivankovich AD, McCarthy R. The effects of fentanyl and vasopressors on anaesthetized dogs receiving MAO inhibitors. Anesth Analg 1984; 63: 192 (Abs).Google Scholar
  57. 57.
    El-Ganzouri AR, Ivankovich AD, Braverman B, McCarthy R. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg 1985; 64: 592–6.PubMedCrossRefGoogle Scholar
  58. 58.
    Michaels I, Serrings M, Shier N, Barash PG. Anesthesia for cardiac surgery in patients receiving monoamine oxidase inhibitors. Anesth Analg 1984; 63: 1041–4.PubMedGoogle Scholar
  59. 59.
    Ayd F. Should monoamine oxidase inhibitors be discontinued preoperatively? Int. Drug Therapy Newsletter 1986; 21(6): 24.Google Scholar
  60. 60.
    Wong KC. Preoperative discontinuation of monoamine oxidase inhibitor therapy: an old wives tale? Sem Anes 1986; 5: 145–8.Google Scholar
  61. 61.
    Sides CA. Hypertension during anaesthesia with monoamine oxidase inhibitors. Anaesthesia 1987; 42: 633–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Mitchell RS. Fatal toxic encephalitis occurring during iproniazid therapy in pulmonary tuberculosis. Ann Int Med 1955; 42: 417–24.PubMedGoogle Scholar
  63. 63.
    Papp C, Benaim S. Toxic effects of iproniazid in a patient with angina. Br Med J 1958; 2: 1070–2.PubMedGoogle Scholar
  64. 64.
    Shee JC. Dangerous potentiation of pethidine by iproniazid and its treatment. Br Med J 1960; 2: 507–9.PubMedGoogle Scholar
  65. 65.
    Palmer H. Potentiation of pethidine. Br Med J 1960; 2: 944.Google Scholar
  66. 66.
    Taylor DC. Alarming reaction to pethidine in patients on phenelzine. Lancet 1962; 2: 401–2.CrossRefGoogle Scholar
  67. 67.
    Denton PH, Borell VM, Edwards NV. Dangers of monoamine oxidase inhibitors. Br Med J 1962; 2:1752.Google Scholar
  68. 68.
    Spencer GT, Smith SE. Dangers of monoamine oxidase inhibitors. Br Med J 1963; 1: 750.PubMedGoogle Scholar
  69. 69.
    Churchill-Davidson HC. Anaesthesia and monoamineoxidase inhibitors. Br Med J 1965; 1: 520.PubMedGoogle Scholar
  70. 70.
    Rogers KJ, Thornton JA. The interaction between monoamine oxidase inhibitors and narcotic analgesics in mice. Br J Pharmacol 1969; 36: 470–80.PubMedGoogle Scholar
  71. 71.
    Dostert P. Myth and reality of the classical MAO inhibitors. Reasons for seeking a new generation.In: Tipton KF, Dostert P, Benedetti MS (Eds). Monoamine oxidase and disease. Prospects for therapy with reversible inhibitors. London: Academic Press, 1984: 9–25.Google Scholar
  72. 72.
    Vickers MD. Anaesthesia and MAO inhibitors. Br Med J 1965; 1: 1126.PubMedGoogle Scholar
  73. 73.
    Penn RG, Rogers KJ. Comparison of the effects of morphine, pethidine and pentazocine in rabbits pretreated with an MAO. Br J Pharmacol 1971; 42: 485.PubMedGoogle Scholar
  74. 74.
    Brown DD, Waldron DH. An unusual reaction to tranylcypromine. Practitioner 1962; 189: 83–5.PubMedGoogle Scholar
  75. 75.
    Baldessarini RJ. Drugs and the treatment of psychiatric disorders.In: Gillman AC, Goodman LS, Gilman A (Eds). The pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980: 427–30.Google Scholar
  76. 76.
    Youssef MS, Wilkinson PA. Epidural fentanyl and monoamine oxidase inhibitors. Anaesthesia 1988; 43: 210–2.PubMedCrossRefGoogle Scholar
  77. 77.
    Hirsch MS, Walter RM, Hasterlik RJ. Subarachnoid hemorrhage following ephedrine and MAO inhibitor. JAMA 1965; 194: 1259.PubMedCrossRefGoogle Scholar
  78. 78.
    Cousins MJ, Maltby JR. Delayed recovery of sympathetic transmission following ten years MAO inhibition. Br J Anaesth 1971; 43: 803–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Hirsch MS, Walter RM, Hauterlik RJ. Subarachnoid hemorrhage following ephedrine and MAO inhibitors. JAMA 1965; 194: 1259.PubMedCrossRefGoogle Scholar
  80. 80.
    Horler AR, Wayne NA. Hypertensive crises due to pargyline and metaraminol. Br Med J 1965; 2: 460–1.PubMedGoogle Scholar
  81. 81.
    Mason A. Fatal reaction associated with tranylcypromine and methylamphetamine. Lancet 1962; 1: 173–7.Google Scholar
  82. 82.
    Cuthbert MF, Greenberg MP, Morley SW. Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors. Br Med J 1969; 1: 404–6.PubMedGoogle Scholar
  83. 83.
    Blackwell B. Hypertensive crisis due to MAO inhibitors. Lancet 1963; 2: 849–51.PubMedCrossRefGoogle Scholar
  84. 84.
    Elis J, Laurence Dr, Manie H, Prichard BNC. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on the blood pressure. Br Med J 1967; 2: 75–8.PubMedGoogle Scholar
  85. 85.
    Hunter KR, Boakes AJ, Laurence Dr, Sterne GM. Monoamine oxidase inhibitors and L-dopa. Br Med J 1970; 3: 338.Google Scholar
  86. 86.
    Horwitz D, Goldberg LI, Sjoerdsma A. Increased blood pressure responses to dopamine and norepinephrine produced by monoamine oxidase inhibitor in man. J Lab Clin Med 1960; 56: 747–53.PubMedGoogle Scholar
  87. 87.
    Janowsky EC, Risen SC, Janowsky DS. Psychotropic agents.In: Smith TY, Miller RD, Corbascio AN (Eds). Drug Interactions in Anesthesia. Philadelphia: Lea and Febinger, 1981: 177–95.Google Scholar
  88. 88.
    Jacobson J. A review of the danger of monoamine oxidase inhibitors, with special reference to anesthesia. S Afr Med J 1965; 39: 10–4.PubMedGoogle Scholar
  89. 89.
    Boakes AJ, Teoh PC, Barar FKS, Benedikter LT, Prichard BNC. Interaction between sympathomimetic amines and antidepressant agents in man. B Med J 1973; 1: 311–5.Google Scholar
  90. 90.
    Wulfsohn NL, Politzer WM. 5-Hydroxytryptamine in anaesthesia. Anaesthesia 1962; 17: 64–8.PubMedCrossRefGoogle Scholar
  91. 91.
    Fouts JR,Brodie BB. On the mechanism of drug potentiation by iproniazid. J Pharmacol Exp Ther 1956; 116–480–5.Google Scholar
  92. 92.
    Gaines GY, Ress DI. Electroconvulsive therapy and anesthetic considerations. Anesth Analg 1986; 65: 1345–56.PubMedCrossRefGoogle Scholar
  93. 93.
    Domino EF, Sullivan TS, Buby ED. Barbiturate intoxication in a patient treated with a MAO inhibitor. Am J Psych 1962; 118:941–3.Google Scholar
  94. 94.
    Bodley PO, Halwax K, Potts L. Low serum pseudocholinesterase levels complicating treatment with phenelzine. Br Med J 1969; 3: 510–2.PubMedCrossRefGoogle Scholar
  95. 95.
    Sjoquist F. Psychotropic. (2) Interaction between monoamine oxidase (MAOI) inhibitors and other substances. Proc R Soc Med 1965; 58: 967.Google Scholar
  96. 96.
    Johnston RR, Eger EI, Wildon C. A comparative interaction of epinephrine with enflurane, isoflurane and halothane in man. Anesth Analg 1976; 55: 709–12.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 1989

Authors and Affiliations

  • Douglas G. Wells
    • 1
    • 2
  • Andrew R. Bjorksten
    • 1
  1. 1.Department of AnaesthesiaAmalgamated Melbourne and Essendon HospitalsMelbourneAustralia
  2. 2.Department of Anaesthesia C/O Post OfficeThe Royal Melbourne HospitalVictoriaAustralia

Personalised recommendations